GlobeNewsWire
21 Aug 2026, 13:05 UTC · 4w ago
Verdict
Headline leans bearish. We score ALNY −1.00 across three claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
3 claims · scored −1 bearish … +1 bullish
Alnylam Pharmaceuticals cut its total projected TTR net product revenues for full-year 2026 by approximately $200 million.
So whatA significant downward revision in revenue guidance for a core product directly impacts valuation and growth expectations.
More negative than 98% of claims this week
Alnylam's stock price declined by over 28% following the release of its second quarter 2026 financial results.
Continue reading
5 related stories
More negative than 96% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 92% of claims this week
Law firm Kessler Topaz Meltzer & Check is investigating Alnylam Pharmaceuticals for potential violations of federal securities laws.
More negative than 81% of claims this week
Which stocks this story touches
More negative than 96% of ticker scores this week
The company reported disappointing financial results, lowered revenue guidance, saw its stock drop 28%, and is now under investigation for potential securities law violations.
More negative than 88% of ticker scores this week
The company is the subject of a securities fraud class action lawsuit.
More negative than 88% of ticker scores this week
The company is the subject of a securities fraud class action lawsuit.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
1d ago
+4.5%
Price is moving against the score
$239.56 vs $229.30 close before publication (Aug 20) · not market-adjusted
ALNY chart →
